Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik

Permanent URI for this collectionhttps://hdl.handle.net/11147/9

Browse

Filters

2007 - 200922010 - 2019282020 - 20234

Settings

Institution Author: search.filters.institutionAuthor.Baran, YusufScopus Q: search.filters.scopusQuartile.Q1

Search Results

Now showing 1 - 10 of 34
  • Article
    Citation - WoS: 3
    Citation - Scopus: 3
    Her2-Specific Peptide (ltvspwy) and Antibody (herceptin) Targeted Core Cross-Linked Micelles for Breast Cancer: a Comparative Study
    (MDPI, 2023) Bayram, N.N.; Ulu, G.T.; Abdulhadi, N.A.; Gürdap, S.; İşoğlu, İ.A.; Baran, Yusuf; İşoğlu, S.D.
    This study aims to prepare a novel breast cancer-targeted micelle-based nanocarrier, which is stable in circulation, allowing intracellular drug release, and to investigate its cytotoxicity, apoptosis, and cytostatic effects, in vitro. The shell part of the micelle is composed of zwitterionic sulfobetaine ((N-3-sulfopropyl-N,N-dimethylamonium)ethyl methacrylate), while the core part is formed by another block, consisting of AEMA (2-aminoethyl methacrylamide), DEGMA (di(ethylene glycol) methyl ether methacrylate), and a vinyl-functionalized, acid-sensitive cross-linker. Following this, a targeting agent (peptide (LTVSPWY) and antibody (Herceptin®)), in varying amounts, were coupled to the micelles, and they were characterized by 1H NMR, FTIR (Fourier-transform infrared spectroscopy), Zetasizer, BCA protein assay, and fluorescence spectrophotometer. The cytotoxic, cytostatic, apoptotic, and genotoxic effects of doxorubicin-loaded micelles were investigated on SKBR-3 (human epidermal growth factor receptor 2 (HER2)-positive) and MCF10-A (HER2-negative). According to the results, peptide-carrying micelles showed a higher targeting efficiency and better cytostatic, apoptotic, and genotoxic activities than antibody-carrying and non-targeted micelles. Also, micelles masked the toxicity of naked DOX on healthy cells. In conclusion, this nanocarrier system has great potential to be used in different drug-targeting strategies, by changing targeting agents and drugs. © 2023 by the authors.
  • Article
    Citation - WoS: 25
    Citation - Scopus: 38
    Biodiversity: the Overlooked Source of Human Health
    (Elsevier, 2023) Linhares, Yuliya; Kaganski, Alexander; Agyare, Christian; Aksan Kurnaz, Işıl; Neergheen, Vidushi; Kolodziejczyk, Bartlomiej; Baran, Yusuf
    Biodiversity is the measure of the variation of lifeforms in a given ecological system. Biodiversity provides ecosystems with the robustness, stability, and resilience that sustains them. This is ultimately essential for our survival because we depend on the services that natural ecosystems provide (food, fresh water, air, climate, and medicine). Despite this, human activity is driving an unprecedented rate of biodiversity decline, which may jeopardize the life-support systems of the planet if no urgent action is taken. In this article we show why biodiversity is essential for human health. We raise our case and focus on the biomedicine services that are enabled by biodiversity, and we present known and novel approaches to promote biodiversity conservation.
  • Conference Object
    Changes in Gene Expression Profiles in Response To Apigenin in Imatinib Sensitive and Resistant Chronic Myeloid Leukemia Cells
    (FERRATA STORTI FOUNDATION, 2013) Baran, Yusuf; Gökbulut, Aysun; Cincin, Zeynep; Çakmakoğlu, Bedia; Kozanoğlu, İlknur
    [No abstract available]
  • Conference Object
    Determination of Cytotoxic and Apoptotic Effects of Caffeic Acid Phenethyl Ester and Gossypol in Combination With Fludarabine at a Molecular Level in Acute Lymphoblastic Leukemia Cells
    (Ferrata Storti Foundation, 2013) Baran, Yusuf; İskender, G.; Pişkin, Özden; Özcan, Mehmet Ali
    [No abstract available]
  • Conference Object
    Diagnostic and Therapeutic Potentials of Expression Levels of Bioactive Sphingolipid Genes in Newly Diagnosed and Drug-Resistant Chronic Myeloid Leukemia Patients
    (Ferrata Storti Foundation, 2013) Baran, Yusuf; Yandım, Melis; Kozanoğlu, İlknur; Özdoğu, Hakan; Pişkin, Özden; Özcan, Mehmet Ali
    [No abstract available]
  • Conference Object
    Immunologically Detection of Bcr/Abl Fusion Protein With Flow Cytometry in K562 Chronic Myeloid Leukemia Cells and Comparison With Rt-Pcr Results
    (Ferrata Storti Foundation, 2013) Kozanoğlu, İlknur; Aygün, B.; Boğa, I.; Cansun, C.; Üstündağ, N.; Baran, Yusuf; Özdoğu, Hakan
    [No abstract available]
  • Conference Object
    Citation - WoS: 1
    A Study of Multiple Drug Resistance Mechanisms Improved Against Bortezomib on Multiple Myeloma Cell Lines in Vitro
    (American Society of Hematology, 2007) Uyuklu, Tolga; Ural, A. Uğur; Sarper, Metal; Avcu, Ferit; Baran, Yusuf; Elçi, Pınar; Akar, Nejat
    The most important problem in the treatment of Multiple Myeloma (MM) is the multi drug resistance (MDR) observed before and after the treatment. For this reason in MM cases an early resistance to treatment can be developed or the disease can relapsed in early period. Yet, there has been no improved drug resistance against proteazom inhibitor Bortezomib (Bor), which is used alone or with other chemotherapeutic agents in resistant or relapsed MM cases
  • Conference Object
    A Novel Agent, Kl-21, Has Significant Anticancer Potential on Chronic Lymphocytic Leukemia Cells but Not on Healthy Cells
    (Ferrata Storti Foundation, 2012) Baran, Yusuf; Gökbulut, Aysun; Yaşar, M.
    [No abstract available]
  • Conference Object
    Antiproliferative and Apoptotic Effects of Resveratrol on Chronic Lymphocytic Leukemia Cells
    (Ferrata Storti Foundation, 2012) Baran, Yusuf; Gökbulut, Aysun; Özcan, Mehmet Ali; Pişkin, Özden; Ünlü, Miray
    [No abstract available]
  • Conference Object
    Suppression of STAT5A and STAT5B Chronic Myeloid Leukemia Cells Via SiRNA and Antisense-Oligonucleotide Applications With the Induction of Apoptosis
    (Wiley, 2014) Kaymaz, Burcin Tezcanli; Selvi, Nur; Gokbulut, Aysun Adan; Aktan, Cagdas; Gunduz, Cumhur; Saydam, Guray; Kosova, Buket
    Signal transducers and activators of transcription ( STAT) proteins function in the JAK/STAT signaling pathway and are activated by phosphorylation. As a result of this signaling event, they affect many cellular processes including cell growth, proliferation, differentiation, and survival. Increases in the expressions of STAT5A and STAT5B play a remarkable role in the development of leukemia in which leukemic cells gain uncontrolled proliferation and angiogenesis ability. At the same time, these cells acquire ability to escape from apoptosis and host immune system. In this study, we aimed to suppress STAT-5A and -5B genes in K562 CML cells by siRNA transfection and antisense oligonucleotides (ODN) targeting and then to evaluate apoptosis rate. Finally, we compared the transfection efficiencies of these approaches. Quantitative RT-PCR and Western blot results indicated that STAT expressions were downregulated at both mRNA and protein levels following siRNA transfection. However, electroporation mediated ODN transfection could only provide limited suppression rates at mRNA and protein levels. Moreover, it was displayed that apoptosis were significantly induced in siRNA treated leukemic cells as compared to ODN treated cells. As a conclusion, siRNA applications were found to be more effective in terms of gene silencing when compared to ODN treatment based on the higher apoptosis and mRNA suppression rates. siRNA application could be a new and alternative curative method as a supporting therapy in CML patients.